Predictions versus high-throughput experiments in T-cell epitope discovery: Competition or synergy?

Expert Review of Vaccines

Volumn 11, Issue 1, 2012, Pages 43-54

  Lundegaard, Claus ^a   Lund, Ole ^a   Nielsen, Morten ^a  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

CTL; epitope; HLA; MHC; Prediction; T cell; vaccine

Indexed keywords

EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR;

ALLELE; COMPUTER MODEL; GENE; HUMAN; IMMUNOASSAY; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE; REVIEW; T LYMPHOCYTE;

COMPUTATIONAL BIOLOGY; EPITOPES, T-LYMPHOCYTE; HIGH-THROUGHPUT SCREENING ASSAYS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; PROTEIN BINDING; RESEARCH;

EID: 83155164579     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.160     Document Type: Review

References (100)

1. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat. Immunol. 12, 509-517 (2011).
2. Flinsenberg TW, Compeer EB, Boelens JJ, Boes M. Antigen cross-presentation: extending recent laboratory findings to therapeutic intervention. Clin. Exp. Immunol. 165, 8-18 (2011).
3. Huang J, Honda W. CED: a conformational epitope database. BMC Immunol. 7, 7 (2006).
4. Sette A, Peters B. Immune epitope mapping in the post-genomic era: lessons for vaccine development. Curr. Opin. Immunol. 19, 106-110 (2007). (Pubitemid 46073693)
5. Ottenhoff TH, Doherty TM, van Dissel JT et al. First in humans: a new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis-specific Th1-cell like responses. Hum. Vaccin. 6, 1007-1015 (2010).
6. Söllner J, Heinzel A, Summer G et al. Concept and application of a computational vaccinologyworkflow. Immunome Res. 6(Suppl. 2), S7 (2010).
7. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat. Rev. Drug Discov. 9, 325-338 (2010).
8. Cantor JR, Yoo TH, Dixit A, Iverson BL, Forsthuber TG, Georgiou G. Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift. Proc. Natl Acad. Sci. USA 108, 1272-1277 (2011).
9. Star B, Nederbragt AJ, Jentoft S et al. The genome sequence of Atlantic cod reveals a unique immune system. Nature 477, 207-210 (2011).
10. Del Val M, Iborra S, Ramos M, Lázaro S. Generation of MHC class 1 ligands in the secretory and vesicular pathways. Cell Mol. Life Sci. 68, 1543-1552 (2011).
11. Mester G, Hoffmann V, Stevanović S. Insights into MHC class 1 antigen processing gained from large-scale analysis of class 1 ligands. Cell Mol. Life Sci. 68, 1521-1532 (2011).
12. Dragovic SM, Hill T, Christianson GJ et al. Proteasomes, TAP, and endoplasmic reticulum-associated aminopeptidase associated with antigen processing control CD4+ Th cell responses by regulating indirect presentation of MHC class 2-restricted cytoplasmic antigens. J. Immunol. 186(12), 6683-6692 (2011).
13. Sijts EJ, Kloetzel PM. The role of the proteasome in the generation of MHC class 1 ligands and immune responses. Cell Mol. Life Sci. 68, 1491-1502 (2011).
14. Lundegaard C, Lund O, Kesmir C, Brunak S, Nielsen M. Modeling the adaptive immune system: predictions and simulations. Bioinformatics 23, 3265-3275 (2007). (Pubitemid 350238877)
15. Diez-Rivero CM, Lafuente EM, Reche PA. Computational analysis and modeling of cleavage by the immunoproteasome and the constitutive proteasome. BMC Bioinformatics 11, 479 (2010).
16. Roder G, Geironson L, Darabi A et al. The outermost N-terminal region of tapasin facilitates folding of major histocompatibility complex class 1. Eur. J. Immunol. 39, 2682-2694 (2009).
17. Roder G, Geironson L, Rasmussen M, Harndahl M, Buus S, Paulsson KM. Tapasin discriminates peptide- HLA-A. *02:01 complexes formed with natural ligands. J. Biol. Chem. doi:10.1074/jbc.M111.230151 (2011) (Epub ahead of print).
18. Van Den Hoorn T, Paul P, Jongsma ML, Neefjes J. Routes to manipulate MHC class 2 antigen presentation. Curr. Opin. Immunol. 23, 88-95 (2011).
19. Call MJ. Small molecule modulators of MHC class 2 antigen presentation: mechanistic insights and implications for therapeutic application. Mol. Immunol. 48, 1735-1743 (2011).
20. Watts C. The endosome-lysosome pathway and information generation in the immune system. Biochim. Biophys. Acta doi:10.1016/j.bbapap.2011.07.006 (2011) (Epub ahead of print).
21. Landsverk OJ, Bakke O, Gregers TF. MHC II and the endocytic pathway: regulation by invariant chain. Scand. J. Immunol. 70, 184-193 (2009).
22. Münz C. Enhancing immunity through autophagy. Ann. Rev. Immunol. 27, 423-449 (2009).
23. Zavasnik-Bergant T, Turk B. Cysteine proteases: destruction ability versus immunomodulation capacity in immune cells. Biol. Chem. 388, 1141-1149 (2007). (Pubitemid 350059624)
24. Conus S, Simon HU. Cathepsins and their involvement in immune responses. Swiss Med. Wkly 140, w13042 (2010).
25. Jørgensen KW, Buus S, Nielsen M. Structural properties of MHC class 2 ligands, implications for the prediction of MHC class 2 epitopes. PLoS One 5, e15877 (2010).
26. Van Endert P. Post-proteasomal and proteasome-independent generation of MHC class 1 ligands. Cell Mol. Life Sci. 68, 1553-1567 (2011).
27. Chemali M, Radtke K, Desjardins M, English L. Alternative pathways for MHC class 1 presentation: a new function for autophagy. Cell Mol. Life Sci. 68, 1533-1541 (2011).
28. Larsen MV, Nielsen M, Weinzierl A, Lund O. TAP-independent MHC class 1 presentation. Curr. Immunol. Rev. 2, 233-245 (2006).
29. Segura E, Villadangos JA. A modular and combinatorial view of the antigen cross-presentation pathway in dendritic cells. Traffic 12(12), 1677-1685 (2011).
30. Amigorena S, Savina A. Intracellular mechanisms of antigen cross presentation in dendritic cells. Curr. Opin. Immunol. 22, 109-117 (2010).
31. Burrows SR, Rossjohn J, McCluskey J. Have we cut ourselves too short in mapping CTL epitopes? Trends Immunol. 27, 11-16 (2006). (Pubitemid 43083559)
32. Sidney J, Peters B, Frahm N, Brander C, Sette A. HLA class 1 supertypes: a revised and updated classification. BMC Immunol. 9, 1471-2172 (2008).
33. Lundegaard C, Lund O, Buus S, Nielsen M. Major histocompatibility complex class 1 binding predictions as a tool in epitope discovery. Immunology 130, 309-318 (2010).
34. Robinson J, Mistry K, McWilliam H, Lopez R, Parham P, Marsh SG. The IMGT/HLA database. Nucleic Acids Res. 39, D1171-D1176 (2011).
35. Nielsen M, Lund O, Buus S, Lundegaard C. MHC class 2 epitope predictive algorithms. Immunology 130, 319-328 (2010).
36. Bordner AJ. Towards universal structure-based prediction of class 2 MHC epitopes for diverse allotypes. PLoS One 5, e14383 (2010).
37. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res. 39, D913-D919 (2011).
38. Sayers EW, Barrett T, Benson DA et al. Database resources of the national center for biotechnology information. Nucleic Acids Res. 39, D38-D51 (2011).
39. Vita R, Zarebski L, Greenbaum JA et al. The immune epitope database 2.0. Nucleic Acids Res. 38, D854-D862 (2010).
40. Scharnagl NC, Klade CS. Experimental discovery of T-cell epitopes: combining the best of classical and contemporary approaches. Exp. Review Vaccin. 6(4), 605-615 (2007). (Pubitemid 47281302)
41. Li Pira G, Ivaldi F, Moretti P, Manca F. High throughput T epitope mapping and vaccine development. J. Biomed. Biotechnol. 2010, 325720 (2010).
42. Hoppes R, Ekkebus R, Schumacher TN, Ovaa H. Technologies for MHC class 1 immunoproteomics. J. Proteom. 73, 1945-1953 (2010).
43. Yewdell JW. Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity 25, 533-543 (2006). (Pubitemid 44529047)
44. Riedl P, Wieland A, Lamberth K et al. Elimination of immunodominant epitopes from multispecific DNA-based vaccinesallows induction of CD8 T cells that have a striking antiviral potential. J. Immunol. 183, 370-380 (2009).
45. Baumgartner CK, Malherbe LP. Antigen-driven T-cell repertoire selection during adaptive immune responses. Immunol. Cell Biol. 89, 54-59 (2011).
46. Dominguez MR, Silveira EL, de Vasconcelos JR et al. Subdominant/cryptic CD8 T cell epitopes contribute to resistance against experimental infection with a human protozoan parasite. PLoS One 6, e22011 (2011).
47. Im EJ, Hong JP, Roshorm Y et al. Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenges. PLoS Pathog. 7, e1002041 (2011).
48. Ruckwardt TJ, Luongo C, Malloy AM et al. Responses against a subdominant CD8+ T cell epitope protect against immunopathology caused by a dominant epitope. J. Immunol. 185, 4673-4680 (2010).
49. Kiecker F, Streitz M, Ay B et al. Analysis of antigen-specific T-cell responses with synthetic peptides -what kind of peptide for which purpose? Hum. Immunol. 65, 523-536 (2004). (Pubitemid 38686777)
50. + and CD4+ T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation. J. Immunother. 34, 307-319 (2011).
51. Casalegno-Garduño R, Schmitt A, Yao J et al. Multimer technologies for detection and adoptive transfer of antigen-specific T cells. Cancer. Immunol. Immunother. 59, 195-202 (2010).
52. Leisner C, Loeth N, Lamberth K et al. One-pot, mix-and-read peptide-MHC tetramers. PLoS One 3, e1678 (2008).
53. Burrows JM, Wynn KK, Tynan FE et al. The impact of HLA-B micropolymorphism outside primary peptide anchor pockets on the CTL response to CMV. Eur. J. Immunol. 37, 946-953 (2007). (Pubitemid 46925332)
54. Schøller J, Singh M, Bergmeier L et al. A recombinant human HLA-class 1 antigen linked to dextran elicits innate and adaptive immune responses. J. Immunol. Methods 360, 1-9 (2010).
55. Neudorfer J, Schmidt B, Huster KM et al. Reversible HLA multimers (streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens. J. Immunol. Methods 320, 119-131 (2007). (Pubitemid 46349106)
56. Harndahl M, Justesen S, Lamberth K, Røder G, Nielsen M, Buus S. Peptide binding to HLA class 1 molecules: homogenous, high-throughput screening, and affinity assays. J. Biomol. Screen 14, 173-180 (2009).
57. Peters B, Bui HH, Frankild S et al. A community resource benchmarking predictions of peptide binding to MHC-I molecules. PLoS Comput. Biol. 2, e65 (2006).
58. Lundegaard C, Hoof I, Lund O, Nielsen M. State of the art and challenges in sequence based T-cell epitope prediction. Immunome. Res. 6(Suppl. 2), S3 (2010).
59. Wang P, Sidney J, Dow C, Mothé B, Sette A, Peters B. A systematic assessment of MHC class 2 peptide binding predictions and evaluation of a consensus approach. PLoS Comput. Biol. 4, e1000048 (2008).
60. Bordner AJ, Abagyan R. Ab initio prediction of peptide-MHC binding geometry for diverse class 1 MHC allotypes. Proteins 63, 512-526 (2006).
61. Zhang H, Wang P, Papangelopoulos N et al. Limitations of Ab initio predictions of peptide binding to MHC class 2 molecules. PLoS One 5, e9272 (2010).
62. Lundegaard C, Lund O, Nielsen M. Prediction of epitopes using neural network based methods. J. Immunol. Methods 374(1-2), 26-34 (2010).
63. Reche PA, Reinherz EL. Definition of MHC supertypes through clustering of MHC peptide-binding repertoires. Methods Mol. Biol. 409, 163-173 (2007).
64. Doytchinova IA, Guan P, Flower DR. Identifiying human MHC supertypes using bioinformatic methods. J. Immunol. 172, 4314-4323 (2004). (Pubitemid 38375246)
65. Heckerman D, Kadie C, Listgarten J. Leveraging information across HLA alleles/ supertypes improves epitope prediction. J. Comput. Biol. 14, 736-746 (2007). (Pubitemid 47221814)
66. Hertz T, Yanover C. Identifying HLA supertypes by learning distance functions. Bioinformatics 23, e148-e155 (2007). (Pubitemid 46189650)
67. Lamberth K, Røder G, Harndahl M et al. The peptide-binding specificity of HLA-A.*3001 demonstrates membership of the HLA-A3 supertype. Immunogenetics 60, 633-643 (2008).
68. Rapin N, Hoof I, Lund O, Nielsen M. MHC motif viewer. Immunogenetics 60, 759-765 (2008).
69. Axelsson-Robertson R, Ahmed RK, Weichold FF et al. Human leukocyte antigens A. 3001 and A. *3002 show distinct peptide-binding patterns of the Mycobacterium tuberculosis protein TB10.4: consequences for immune recognition. Clin. Vaccin. Immunol. 18, 125-134 (2011).
70. Zhang H, Lundegaard C, Nielsen M. Pan-specific MHC class 1 predictors: a benchmark of HLA class 1 pan-specific prediction methods. Bioinformatics 25, 83-89 (2009).
71. Zhang L, Udaka K, Mamitsuka H, Zhu S. Toward more accurate pan-specific MHC-peptide binding prediction: a review of current methods and tools. Brief. Bioinform. doi:10.1093/bib/bbr060 (2011) (Epub ahead of print).
72. Hoof I, Peters B, Sidney J et al. NetMHCpan, a method for MHC class 1 binding prediction beyond humans. Immunogenetics 61, 1-13 (2009).
73. Nielsen M, Lundegaard C, Blicher T et al. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One 2, e796 (2007).
74. Hoof I, Pérez CL, Buggert M et al. Interdisciplinary analysis of HIV-specific CD8+ T cell responses against variant epitopes reveals restricted TCR promiscuity. J. Immunol. 184(9), 5383-5391 (2010).
75. Karosiene E, Lundegaard C, Lund O, Nielsen M. NetMHCcons: a consensus method for the major histocompatibility complex class I predictions. Immunogenetics doi:10.1007/s00251-011- 0579-8 (2011) (Epub ahead of print).
76. Wu C, Zanker D, Valkenburg S et al. Systematic identification of immunodominant CD8+ T-cell responses to influenza A virus in HLA-A2 individuals. Proc. Natl Acad. Sci. USA doi:0.1073/pnas.1105624108 (2011) (Epub ahead of print).
77. Lundegaard C, Lund O, Nielsen M. Accurate approximation method for prediction of class 1 MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers. Bioinformatics 24, 1397-1398 (2008). (Pubitemid 351737147)
78. Erup Larsen M, Kloverpris H, Stryhn A et al. HLArestrictor - a tool for patient-specific predictions of HLA restriction elements and optimal epitopes within peptides. Immunogenetics 63, 43-55 (2011).
79. Stranzl T, Larsen MV, Lundegaard C, Nielsen M. NetCTLpan: pan-specific MHC class 1 pathway epitope predictions. Immunogenetics 62, 357-368 (2010).
80. Diez-Rivero CM, Chenlo B, Zuluaga P, Reche PA. Quantitative modeling of peptide binding to TAP using support vector machine. Proteins 78, 63-72 (2010).
81. Schmid BV, Kesmir C, de Boer RJ. The specificity and polymorphism of the MHC class 1 prevents the global adaptation of HIV-1 to the monomorphic proteasome and TAP. PLoS One 3, e3525 (2008).
82. Nielsen M, Lundegaard C, Lund O, Kesmir C. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics 57, 33-41 (2005). (Pubitemid 40591245)
83. Wang P, Sidney J, Kim Y et al. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinform. 11, 568 (2010).
84. Nielsen M, Justesen S, Lund O, Lundegaard C, Buus S. NetMHCIIpan-2.0 - improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure. Immunome. Res. 6, 9 (2010).
85. Vollers SS, Stern LJ. Class 2 major histocompatibility complex tetramer staining: progress, problems, and prospects. Immunology 123, 305-313 (2008). (Pubitemid 351171199)
86. James EA, LaFond R, Durinovic-Bello I, Kwok W. Visualizing antigen specific CD4+ T cells using MHC class 2 tetramers. J. Vis. Exp. 6(25), pii: 1167 (2009).
87. Sylvester-Hvid C, Nielsen M, Lamberth K et al. SARS CTL vaccine candidates; HLA supertype-, genome-wide scanning and biochemical validation. Tis. Antigens 63, 395-400 (2004). (Pubitemid 38659570)
88. Zhang GL, Ansari HR, Bradley P et al. Machine learning competition in immunology - prediction of HLA class 1 molecules. J. Immunol. Methods 374(1-2), 1-4 (2011).
89. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152, 163-175 (1994).
90. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50, 213-219 (1999). (Pubitemid 30099526)
91. Wang M, Lamberth K, Harndahl M et al. CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening. Vaccine 25, 2823-2831 (2007). (Pubitemid 46420615)
92. Wang M, Tang ST, Lund O, Dziegiel MH, Buus S, Claesson MH. High-affinity human leucocyte antigen class 1 binding variola-derived peptides induce CD4+ T cell responses more than 30 years post-vaccinia virus vaccination. Clin. Exp. Immunol. 155, 441-446 (2009).
93. Moutaftsi M, Peters B, Pasquetto V et al. A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to Vaccinia virus. Nat. Biotechnol. 24, 817-819 (2006).
94. Vordermeier M, Whelan AO, Hewinson RG. Recognition of mycobacterial epitopes by T cells across mammalian species and use of a program that predicts human HLA-DR binding peptides to predict bovine epitopes. Infect. Immun. 71, 1980-1987 (2003). (Pubitemid 36368731)
95. Pedersen LE, Harndahl M, Rasmussen M et al. Porcine major histocompatibility complex (MHC) class 1 molecules and analysis of their peptide-binding specificities. Immunogenetics 63(12), 821-834 (2011).
96. Buggert, M, Norstrom M, Lundegaard C, Lund O, Nielsen M, Karlsson AC. Interdisciplinary evaluation of broadly-reactive HLA class II restricted epitopes eliciting hiv-specific CD4+T cell responses. AIDS Res. Hum. Retroviruses (2011) (In Press).
97. Perez CL, Larsen MV, Gustafsson R et al. Broadly immunogenic HLA class 1 supertype-restricted elite CTL epitopes recognized in a diverse population infected with different HIV-1 subtypes. J. Immunol. 180, 5092-5100 (2008).
98. Gowthaman U, Agrewala JN. In silico methods for predicting T-cell epitopes: Dr Jekyll or Mr Hyde? Expert Rev. Proteom. 6(5), 527-537 (2009).
99. Colantonio AD, Bimber BN, Neidermyer WJ et al. KIR polymorphisms modulate peptide-dependent binding to an MHC class 1 ligand with a Bw6 motif. PLoS Pathog. 7, e1001316 (2011).
100. Harndahl M, Rasmussen M, Roder G, Buus S. Real-time, high-throughput measurements of peptide-MHC-I dissociation using a scintillation proximity assay. J. Immunol. Methods 374(1-2), 5-12 (2010).